
Opinion|Videos|April 25, 2024
Adverse Event Profile and Tolerability of Fruquintinib Based on FRESCO-2 Trial
Arvind Dasari, MD, explores the adverse event profile of Fruquintinib, highlighting its apparent tolerability, while emphasizing the importance of gathering real-world data to further assess the adverse event profile of this medication in clinical practice.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Priority Review to Dato-DXd First-Line Metastatic TNBC
2
FDA Accepts NDA of Zanzalintinib Combo for Pretreated Metastatic CRC
3
Dr Shubham Pant Highlights Progress and Promise in Pancreatic Cancer Treatment
4
Gemogenovatucel-T Triples Overall Survival in High-Risk HRP Ovarian Cancer
5



















